Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all ...
The FDA has accepted for review the New Drug Application for SYD-101 (atropine sulfate) to slow the progression of myopia in children.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback